Biovitrum Wins Contract to Manufacture Pharmaceutical Substance For Resistentia's clinical Phase III Trials of New Protein-Based Drug Candidate for the Treatment of Allergy.

Business Wire › November 08, 2006

Linked as:

Extract

Biovitrum Wins Contract to Manufacture Pharmaceutical Substance For Resistentia's clinical Phase III Trials of New Protein-Based Drug Candidate for the Treatment of Allergy.

STOCKHOLM, Sweden -- Biopharma company Biovitrum (STO:BVT), listed on the Stockholm Stock Exchange since September 15, 2006, has entered an agreement with the Uppsala-based biotech company Resistentia Pharmaceuticals AB for process d...

See the full content of this document